BNTX$105.29
Chart
Performance
Key Stats
AI BNTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyBioNTech SE exhibits strong thematic potential in biotechnology and infectious disease solutions. Fundamentally, it has significant cash reserves but recent profitability has been volatile, impacted by the post-pandemic landscape. Technicals show a stock in a downtrend but with recent upward momentum. Investors should consider the company's innovation pipeline and the fluctuating demand for its core products.
Thematic
BioNTech is a leader in mRNA technology, with a strong focus on oncology and infectious diseases, positioning it well for future therapeutic advancements and pandemic preparedness.
Fundamental
BioNTech possesses a strong balance sheet with substantial cash reserves, but its earnings have been highly volatile. Valuation metrics are mixed, reflecting market uncertainty about future growth beyond COVID-19 vaccines.
Technical
The stock has experienced significant volatility. While showing some recent positive momentum, it remains below its 52-week high and is navigating various support and resistance levels. Caution is advised due to the mixed technical indicators.
| Factor | Score |
|---|---|
| mRNA Technology Advancement | 95 |
| Oncology Pipeline | 90 |
| Infectious Disease Preparedness | 75 |
| Biotechnology Innovation | 88 |
| Partnerships and Collaborations | 82 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 15 |
| Growth | 25 |
| Balance Sheet Health | 95 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 65 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 50 |
| 52-Week Range | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (8)
Strong Short-Term Performance
The stock has shown strong positive performance over the 5-day (5.2%) and 1-month (7.94%) periods, indicating recent positive investor sentiment and momentum.
Significant Year-over-Year Growth
The stock has delivered a substantial 33.31% return over the past year, significantly outperforming broader market indices and indicating strong investor confidence.
Bearish Points (8)
Inconsistent EPS Performance
Earnings per share (EPS) have been highly volatile, with significant negative EPS reported in Q2 2024 (-1.31) and Q1 2024 (-3.36), coupled with a substantial negative surprise in Q3 2024 (-66.08%), indicating significant profitability challenges and unpredictability.
Negative Profitability in Recent Periods
The company reported a net loss of -$665.3 million in 2024Q4, with a negative net margin of -24.2%, and a significant net loss in Q1 2025 (-$415.8 million), signaling a current downturn in profitability.
Calendar
June 2022
2
Ex-Dividend Date
June 2022
17
Next Dividend Date
August 2025
4
Next Earnings Date
H: $3.09
A: $-1.90
L: $-3.33
H: 1.57B
A: 263.65M
L: 82.26M
Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Seasonals
Price Target
136.23 USD
The 39 analysts offering 1 year price forecasts for BNTX have a max estimate of 174.55 and a min estimate of 85.64.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct partner and co-developer of BioNTech's flagship COVID-19 vaccine, Comirnaty, representing a highly interdependent relationship.
Weight: 95
Primary direct competitor in mRNA vaccine technology and development, often compared for pipeline and market share.
Weight: 90
Another key competitor in the development and application of mRNA technologies for vaccines and therapeutics.
Weight: 85
Developing mRNA-based cancer vaccines and therapeutics, directly competing with BioNTech's oncology pipeline.